Recent developments in the pharmacological treatment of advanced pancreatic cancer (Q35144004)

6 August 2017

1 reference

title

Recent developments in the pharmacological treatment of advanced pancreatic cancer (English)

1 reference

6 August 2017

1 reference

Matthew H Kulke

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

983-992

1 reference

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

The pemetrexed/gemcitabine combination in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.983

10.1517/13543784.12.6.983

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference